All In Biotech

Drug Trial Radar · NCT07248865

A Phase 1 Study of CLYM116 in Normal Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose (SAD) and Multiple-Ascending-Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injection(s) of CLYM116 in Normal Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Dec 2, 2025

Primary completion

Jul 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Climb Bio, Inc.Industry
Sponsor type
Industry
First posted
Nov 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • CLYM116Drug

    CLYM116 to be administered by SC injection

  • PlaceboDrug

    Placebo solution to be administered at a matching volume by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of single and multiple ascending doses of CLYM116 in healthy volunteers Incidence of treatment-emergent adverse eventsTime frame: From Screening through to Day 85, or final follow-up visit
  2. Incidence of injection site reactions Number of injection site reactionsTime frame: From Baseline through to Day 4 and Day 15 to Day 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Brisbane

    Brisbane, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.